GlobalData Plc

In October 2017, the Republican Party opted not to present its most recent healthcare bill, the Graham-Cassidy Bill, to the US Senate, once again halting its efforts to repeal the Affordable Care Act (ACA). As the latest attempt of many to replace the ACA, the bill has been highly controversial. Among the most debated measures in the bill is a provision for changing the federal government’s funding scheme for Medicaid programs, designed to restrict the potential for increases in federal spending on Medicaid.

As GlobalData, a leading data and analytics company observes this could have a significant impact on the US pharmaceutical market.

Jack Evans, Healthcare Analyst at GlobalData commented, ‘‘Based on the assumption that a number of states would be unable to continue to offer their current level of Medicaid coverage, a number of inferences for the US pharmaceutical market can be made. A reduction in pharmaceutical use among the population that will be newly uninsured is likely, as these would largely be low-income individuals without other means of payment. Reductions in spending on chronic or non-life-threatening diseases are expected to be among the highest to come from the bill, as these areas are some of the largest beneficiaries of the expanded Medicaid coverage.’’

With the expiry of special circumstances associated with the Budget reconciliation instruction, that allow a bill to be passed with a simple senate majority (51 votes) rather than the 60 votes normally needed; the efforts to repeal the ACA will likely cease in the short term.
Evans continues, ‘‘The Republican Party can pass new budget-passing measures to reintroduce these arrangements, but with the administration’s current focus on tax reform, we believe this to be unlikely in the short to medium term.’’

One strategy put forth by the bill is a per-capita cap on funding, meaning that states would receive a set amount of funding per Medicaid-eligible individual. The per-capita funding would initially increase at a rate higher than the healthcare inflation rate, but would start to reduce in 2025. The bill also allows for states to switch from the per-capita funding arrangement to a block-funding scenario, where each state receives a set amount of funding each year, regardless of Medicaid enrollment numbers; however, in this scenario, the rate of growth is limited from its inception rather than beginning to reduce in 2025.

Another aspect of the block-funding scenario would be the method of distribution of the federal funds set aside for Medicaid every year. Currently, states that offer expanded Medicaid coverage enjoy a more generous federal funding match. Under the Graham-Cassidy Bill, this federal funding match would be phased out, and some of the resulting savings would be redistributed to states that have chosen not to offer expanded Medicaid programs. The result of this would be severe budget shortfalls for states that have offered expanded Medicaid coverage by lowering the requirements for entry into the program. States facing funding shortfalls would have to make decisions whether to find alternative funding for expanded Medicaid services, or roll back to provide only the federal minimum Medicaid coverage.

The ACA and its associated federal funding will continue to be utilised until the Republican Party can settle its internal differences and agree on a bill that appeals to enough Senators to pass.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends…